Judge OKs $54M Aggrenox Settlement In Pay-For-Delay Suit
Law360 (July 20, 2018, 12:21 PM EDT) -- A Connecticut federal judge has signed off on a $54 million settlement between indirect purchasers of stroke prevention medicine Aggrenox and drugmakers Teva Pharmaceutical and Boehringer Ingelheim to end allegations the companies blocked generic alternatives to the drug from coming to the market.
U.S. District Judge Stefan R. Underhill on Thursday approved the deal, bringing an end to the indirect buyers' claims in sprawling multidistrict litigation accusing Teva Pharmaceutical Industries Ltd. and Boehringer Ingelheim Pharmaceuticals Inc. of orchestrating a $120 million pay-for-delay deal to keep generic versions of Aggrenox off the market.
The settlement doesn't cover a number insurance companies, including Aetna Inc., Cigna Health...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!